Related Experiment Video

Updated: May 22, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice

Juho Lee1, Changkyu Lee, Tae Hyung Kim

  • 1College of Pharmacy, Pusan National University, Jangjeon-dong, Geumjeong-gu, Busan 609-735, Republic of Korea.

Regulatory Peptides
|May 8, 2012
PubMed

Insights

Palmitic acid-modified exendin-4 (Pal-Ex4) causes prolonged hypoglycemia in type 2 diabetic mice compared to native Ex4. This long-acting inhalation candidate shows delayed absorption and potential for diabetes treatment.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Drug Delivery

Background:

  • Type 2 diabetes mellitus (T2DM) management requires effective glucose-lowering agents.
  • Exendin-4 (Ex4) is a glucagon-like peptide-1 receptor agonist used in T2DM treatment.
  • Pulmonary drug delivery offers an alternative administration route for therapeutic agents.

Purpose of the Study:

  • To evaluate and compare the hypoglycemic effects of pulmonary-administered palmitic acid-modified exendin-4 (Pal-Ex4) versus native Ex4.
  • To assess the pharmacokinetic profile and duration of action of Pal-Ex4 following inhalation in a T2DM mouse model.

Main Methods:

  • Type 2 diabetic db/db mice received intratracheal administration of Pal-Ex4 or Ex4 via microsprayer.
  • Doses of 75 or 150 nmol/kg were administered in 50 μl solution.
  • Lung deposition and absorption were monitored using infrared imaging of Cy5.5-labeled peptides.

Main Results:

  • Pal-Ex4 induced significantly greater hypoglycemia than native Ex4 (3.4x and 2.3x at 75 and 150 nmol/kg, respectively).
  • The time for blood glucose level (BGL) rebound to >150 mg/dl was 3.5 times longer for Pal-Ex4 (18.1 h vs. 5.2 h at 150 nmol/kg).
  • Pal-Ex4 exhibited delayed lung absorption and slower BGL nadir attainment (~8 h vs. 4 h), with minimal kidney distribution up to 8 hours post-administration.

Conclusions:

  • Prolonged hypoglycemia from Pal-Ex4 is attributed to delayed pulmonary absorption and potential albumin binding.
  • Pal-Ex4 demonstrates potential as a long-acting inhaled therapeutic for type 2 diabetes.
  • Pulmonary delivery of modified exendin-4 offers a promising strategy for sustained glycemic control.

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...